Previous 10 | Next 10 |
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FD...
Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...
2024-01-24 08:40:39 ET More on Rezolute Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study Rezolute secures innovation passport designation from U.K. for RZ358 treating hypoglycemia Seeking Alpha’s Quant Rating on Rezolute ...
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, t...
2024-01-23 09:39:10 ET More on Rezolute Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute Read...
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare ...
REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the initiation of sunRIZE, a pivotal Phase 3...
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Ph...
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index 56% lower th...
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that the underwr...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of i...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...